| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
15,000,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1431 - $0.1431 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Pulmatrix is a clinical-stage biotechnology company focused on the discovery and development of inhaled therapeutic products intended to prevent and treat respiratory and other diseases. Co. designs and develops inhaled therapeutic products based on its dry powder delivery technology, inhaled Small Particles Easily Respirable and Emitted (iSPERSE™), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE™ powders are engineered to be small, dense particles. iSPERSE™ powders can be used with dry powder inhaler technologies and can be formulated with a range of drug substances including small molecules and biologics.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Siegert Michelle |
Vice President, FinanceOfficer |
• – – |
2019-11-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,186 |
|
- |
|
| Batycky Richard P. |
Director |
– • – |
2019-11-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
492 |
|
- |
|
| Polaris Venture Partners Special Founders Fund V, |
10% Owner |
– – • |
2018-04-03 |
4 |
B |
$0.00 |
$0 |
I/I |
1,150,000 |
34,587 |
1.42 |
- |
|
| Iwicki Mark T |
Director |
– • – |
2018-04-03 |
4 |
B |
$0.00 |
$0 |
D/D |
307,000 |
307,000 |
2.31 |
- |
|
| Sherman Matthew L |
Director |
– • – |
2018-04-03 |
4 |
B |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
2.31 |
- |
|
| Nelsen Robert |
Former 10% owner |
– – – |
2018-04-03 |
4 |
B |
$0.00 |
$0 |
I/I |
1,150,000 |
3,436,456 |
0.01 |
- |
|
| Hava David L. |
Chief Scientific Officer |
• – – |
2017-03-22 |
4 |
OE |
$2.21 |
$5,001 |
D/D |
2,263 |
2,263 |
|
- |
|
| Clarke Robert W. |
Chief Executive Officer |
• • – |
2017-03-22 |
4 |
OE |
$2.21 |
$10,000 |
D/D |
4,525 |
4,525 |
|
- |
|
| Oculus Innovative Sciences, Inc. |
10% Owner |
– – • |
2015-06-17 |
4 |
S |
$2.75 |
$2,536,875 |
D/D |
(922,500) |
0 |
|
- |
|
| Oculus Innovative Sciences, Inc. |
10% Owner |
– – • |
2015-06-16 |
4 |
S |
$2.75 |
$2,000,625 |
D/D |
(727,500) |
922,500 |
|
- |
|
| Rocklage Scott M |
Director |
– • – |
2015-06-16 |
4 |
B |
$6.88 |
$266,784 |
I/I |
38,805 |
168,873 |
2.1 |
- |
|
| Maki David |
Director |
– • – |
2015-06-16 |
4 |
B |
$6.88 |
$500,156 |
I/I |
72,750 |
218,194 |
2.1 |
- |
|
| Nelsen Robert |
10% Owner |
– – • |
2015-06-16 |
4 |
B |
$6.88 |
$500,156 |
I/I |
72,750 |
2,286,456 |
1.5 |
- |
|
| Polaris Venture Partners Special Founders Fund V, |
10% Owner |
– – • |
2015-06-15 |
4/A |
B |
$6.88 |
$508,998 |
I/I |
74,036 |
52,722 |
1.5 |
- |
|
| Polaris Venture Partners Special Founders Fund V, |
10% Owner |
– – • |
2015-06-15 |
4 |
B |
$6.88 |
$733,514 |
I/I |
106,693 |
52,692 |
1.5 |
- |
|
| Polaris Venture Partners Special Founders Fund V, |
10% Owner |
– – • |
2015-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
3,923,539 |
51,330 |
|
- |
|
| Rocklage Scott M |
Director |
– • – |
2015-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
1,322,222 |
164,058 |
|
- |
|
| Clarke Robert W. |
Chief Executive Officer |
• • – |
2015-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
18,667 |
18,667 |
|
- |
|
| Hava David L. |
Chief Scientific Officer |
• – – |
2015-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,863 |
4,863 |
|
- |
|
| Maki David |
Director |
– • – |
2015-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
363,638 |
181,819 |
|
- |
|
| Nelsen Robert |
10% Owner |
– – • |
2015-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
2,213,706 |
2,213,706 |
|
- |
|
| Oculus Innovative Sciences, Inc. |
10% Owner |
– – • |
2015-03-23 |
4 |
S |
$2.75 |
$962,500 |
D/D |
(350,000) |
1,650,000 |
|
- |
|
| French Gregory M |
Director |
– • – |
2014-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
58,000 |
58,000 |
|
- |
|
| Conley Richard K |
Director |
– • – |
2014-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
58,000 |
58,000 |
|
- |
|
| Harish Sameer |
Chief Financial Officer |
• – – |
2014-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
74,600 |
74,600 |
|
- |
|
26 Records found
|
|
Page 1 of 2 |
|
|
